Literature DB >> 26788234

Investigating the ability of multiparametric MRI to exclude significant prostate cancer prior to transperineal biopsy.

Eva M Serrao1, Tristan Barrett2, Karan Wadhwa3, Deepak Parashar4, Julia Frey3, Brendan C Koo5, Anne Y Warren6, Andrew Doble3, Christof Kastner3, Ferdia A Gallagher7.   

Abstract

INTRODUCTION: We characterized false negative prostate magnetic resonance imaging (MRI) reporting by using histology derived from MRI-transrectal ultrasound (TRUS)-guided transperineal (MTTP) fusion biopsies.
METHODS: In total, 148 consecutive patients were retrospectively reviewed. Men underwent multiparametric MRI (mpMRI), reported by a consultant/attending radiologist in line with European Society of Urogenital Radiology (ESUR) standards. MTTP biopsy of the lesions was performed according to the Ginsburg recommendations. Cases with an MRI-histology mismatch were identified and underwent a second read by an experienced radiologist. A third review was performed with direct histology comparison to determine a true miss from an MRI-occult cancer. Statistical analysis was performed with McNemar's test.
RESULTS: False negative lesions were identified in 29 MRI examinations (19.6%), with a total of 46 lesions. Most false negative lesions (21/46) were located in the anterior sectors of the prostate. The second read led to a significant decrease of false-negative lesions with 7/29 further studies identified as positive on a patient-by-patient basis (24.1% of studies, p = 0.016) and 11/46 lesions (23.9%; p = 0.001). Of these, 30 lesions following the first read and 23 lesions after the second read were considered significant cancer according to the University College London criteria. However, on direct comparison with histology, most lesions were MRI occult.
CONCLUSION: We demonstrate that MRI can fail to detect clinically relevant lesions. Improved results were achieved with a second read but despite this, a number of lesions remain MRI-occult. Further advances in imaging are required to reduce false negative results.

Entities:  

Year:  2015        PMID: 26788234      PMCID: PMC4707904          DOI: 10.5489/cuaj.2895

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN: 1911-6470            Impact factor:   1.862


  45 in total

1.  Definitions of terms, processes and a minimum dataset for transperineal prostate biopsies: a standardization approach of the Ginsburg Study Group for Enhanced Prostate Diagnostics.

Authors:  Timur H Kuru; Karan Wadhwa; Richard Tsung Meng Chang; Lina Maria Carmona Echeverria; Matthias Roethke; Alexander Polson; Giles Rottenberg; Brendan Koo; Edward M Lawrence; Jonas Seidenader; Vincent Gnanapragasam; Richard Axell; Wilfried Roth; Anne Warren; Andrew Doble; Gordon Muir; Rick Popert; Heinz-Peter Schlemmer; Boris A Hadaschik; Christof Kastner
Journal:  BJU Int       Date:  2013-06-17       Impact factor: 5.588

2.  A novel stereotactic prostate biopsy system integrating pre-interventional magnetic resonance imaging and live ultrasound fusion.

Authors:  Boris A Hadaschik; Timur H Kuru; Corina Tulea; Philip Rieker; Ionel V Popeneciu; Tobias Simpfendörfer; Johannes Huber; Pawel Zogal; Dogu Teber; Sascha Pahernik; Matthias Roethke; Patrik Zamecnik; Wilfried Roth; Georgios Sakas; Heinz-Peter Schlemmer; Markus Hohenfellner
Journal:  J Urol       Date:  2011-10-19       Impact factor: 7.450

3.  Combined multiparametric MRI and targeted biopsies improve anterior prostate cancer detection, staging, and grading.

Authors:  Adil Ouzzane; Philippe Puech; Laurent Lemaitre; Xavier Leroy; Pierre Nevoux; Nacim Betrouni; Georges-Pascal Haber; Arnauld Villers
Journal:  Urology       Date:  2011-08-16       Impact factor: 2.649

4.  Dynamic contrast-enhanced-magnetic resonance imaging evaluation of intraprostatic prostate cancer: correlation with radical prostatectomy specimens.

Authors:  Philippe Puech; Eric Potiron; Laurent Lemaitre; Xavier Leroy; Georges-Pascal Haber; Sebastien Crouzet; Kazumi Kamoi; Arnauld Villers
Journal:  Urology       Date:  2009-09-20       Impact factor: 2.649

5.  Significant discrepancies between diagnostic and pathologic Gleason sums in prostate cancer: the predictive role of age and prostate-specific antigen.

Authors:  Brandon K Isariyawongse; Leon Sun; Lionel L Bañez; Cary Robertson; Thomas J Polascik; Kelly Maloney; Craig Donatucci; David Albala; Vladimir Mouraviev; John F Madden; Judd W Moul
Journal:  Urology       Date:  2008-04-02       Impact factor: 2.649

6.  Needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence.

Authors:  Gabriel P Haas; Nicolas Barry Delongchamps; Richard F Jones; Vishal Chandan; Angel M Serio; Andrew J Vickers; Mary Jumbelic; Gregory Threatte; Rus Korets; Hans Lilja; Gustavo de la Roza
Journal:  J Natl Cancer Inst       Date:  2007-09-25       Impact factor: 13.506

7.  Saturation biopsies on autopsied prostates for detecting and characterizing prostate cancer.

Authors:  Nicolas B Delongchamps; Gustavo de la Roza; Richard Jones; Mary Jumbelic; Gabriel P Haas
Journal:  BJU Int       Date:  2008-08-01       Impact factor: 5.588

Review 8.  PI-RADS version 2: what you need to know.

Authors:  T Barrett; B Turkbey; P L Choyke
Journal:  Clin Radiol       Date:  2015-07-29       Impact factor: 2.350

9.  Intermixed normal tissue within prostate cancer: effect on MR imaging measurements of apparent diffusion coefficient and T2--sparse versus dense cancers.

Authors:  Deanna L Langer; Theodorus H van der Kwast; Andrew J Evans; Laibao Sun; Martin J Yaffe; John Trachtenberg; Masoom A Haider
Journal:  Radiology       Date:  2008-12       Impact factor: 11.105

10.  ESUR prostate MR guidelines 2012.

Authors:  Jelle O Barentsz; Jonathan Richenberg; Richard Clements; Peter Choyke; Sadhna Verma; Geert Villeirs; Olivier Rouviere; Vibeke Logager; Jurgen J Fütterer
Journal:  Eur Radiol       Date:  2012-02-10       Impact factor: 5.315

View more
  6 in total

Review 1.  Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools.

Authors:  Jeffrey J Tosoian; Stacy Loeb; Jonathan I Epstein; Baris Turkbey; Peter L Choyke; Edward M Schaeffer
Journal:  Am Soc Clin Oncol Educ Book       Date:  2016

2.  The Prostate Health Index adds predictive value to multi-parametric MRI in detecting significant prostate cancers in a repeat biopsy population.

Authors:  V J Gnanapragasam; K Burling; A George; S Stearn; A Warren; T Barrett; B Koo; F A Gallagher; A Doble; C Kastner; R A Parker
Journal:  Sci Rep       Date:  2016-10-17       Impact factor: 4.379

3.  Comparison of initial and tertiary centre second opinion reads of multiparametric magnetic resonance imaging of the prostate prior to repeat biopsy.

Authors:  Nienke L Hansen; Brendan C Koo; Ferdia A Gallagher; Anne Y Warren; Andrew Doble; Vincent Gnanapragasam; Ola Bratt; Christof Kastner; Tristan Barrett
Journal:  Eur Radiol       Date:  2016-10-24       Impact factor: 5.315

4.  Utilization of Multiparametric MRI of Prostate in Patients under Consideration for or Already in Active Surveillance: Correlation with Imaging Guided Target Biopsy.

Authors:  Jinxing Yu; Ann S Fulcher; Sarah Winks; Mary A Turner; William Behl; Anna Lee Ware; Nitai D Mukhopadhyay; Candice Kim; Christopher Jackson; Harnek S Bajaj; Lance J Hampton
Journal:  Diagnostics (Basel)       Date:  2020-06-29

5.  Evaluation of transabdominal and transperineal ultrasound-derived prostate specific antigen (PSA) density and clinical utility compared to MRI prostate volumes: A feasibility study.

Authors:  Maria Pantelidou; Iztok Caglic; Anne George; Oleg Blyuss; Vincent J Gnanapragasam; Tristan Barrett
Journal:  PLoS One       Date:  2022-09-09       Impact factor: 3.752

6.  Multicenter Multireader Evaluation of an Artificial Intelligence-Based Attention Mapping System for the Detection of Prostate Cancer With Multiparametric MRI.

Authors:  Sherif Mehralivand; Stephanie A Harmon; Joanna H Shih; Clayton P Smith; Nathan Lay; Burak Argun; Sandra Bednarova; Ronaldo Hueb Baroni; Abdullah Erdem Canda; Karabekir Ercan; Rossano Girometti; Ercan Karaarslan; Ali Riza Kural; Andrei S Purysko; Soroush Rais-Bahrami; Victor Martins Tonso; Cristina Magi-Galluzzi; Jennifer B Gordetsky; Ricardo Silvestre E Silva Macarenco; Maria J Merino; Berrak Gumuskaya; Yesim Saglican; Stefano Sioletic; Anne Y Warren; Tristan Barrett; Leonardo Bittencourt; Mehmet Coskun; Chris Knauss; Yan Mee Law; Ashkan A Malayeri; Daniel J Margolis; Jamie Marko; Derya Yakar; Bradford J Wood; Peter A Pinto; Peter L Choyke; Ronald M Summers; Baris Turkbey
Journal:  AJR Am J Roentgenol       Date:  2020-08-05       Impact factor: 3.959

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.